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Background: The purpose of this paper was to demonstrate the use of an online service for 
conducting a systematic review and meta-analysis of the efficacy of topical prostaglandin analogs 
in reducing intraocular pressure (IOP) in glaucoma and ocular hypertension.
Methods: An online service provider (Doctor Evidence) reviewed and extracted data from the 
peer-reviewed literature through September 2009. Randomized controlled studies of at least 
three months’ duration assessing at least two prostaglandin analogs in patients with primary 
open-angle glaucoma, ocular hypertension, or normal-tension glaucoma were included. The 
primary endpoint was mean IOP. Summary estimates were created using random-effects models. 
The Q Chi-square test was used to assess statistical heterogeneity.
Results: Sixteen studies satisfied the inclusion criteria and were analyzed. On average, greater 
IOP-lowering was seen with bimatoprost relative to latanoprost (1 mmHg, P = 0.025) and travo-
prost (0.8 mmHg, P = 0.033) based on mean IOP after 12–26 weeks of treatment. No statistical 
difference was observed in IOP-lowering between latanoprost and travoprost (P = 0.841).   Findings 
were similar to previously published meta-analyses of topical prostaglandin analogs.
Conclusion: Systematic reviews relying on meta-analytic techniques to create summary 
statistics are considered to be the “gold standard” for synthesizing evidence to support clinical 
decision-making. However, the process is time-consuming, labor-intensive, and outside the 
capability of most formulary managers. We have demonstrated the effectiveness of a commercial 
service that facilitates the process of conducting such reviews.
Keywords: evidence-based medicine, meta-analysis, review, systematic, prostaglandin analogs, 
glaucoma
Introduction
Evidence-based formulary decisions require systematic review of the peer-reviewed 
medical literature and meta-analysis to pool data across clinical studies. This type of 
data review and analysis is time-consuming, labor-intensive, and requires special-
ized statistical expertise, putting such work outside the capability of most formulary 
  managers. Furthermore, the dynamic nature of the medical literature means that today’s 
systematic review, which required months and considerable resources to complete, 
may be outdated within weeks of completion.
Use of a web-based provider of systematic review services and analysis software 
may ease the process of developing systematic reviews and meta-analyses, and thus 
facilitate the critical appraisal of current data for evidence-based formulary   decisions. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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One such   service provider, Doctor Evidence (Doctor Evidence 
LLC, Santa Monica, CA), builds evidence databases from 
clinical studies on a web-based platform. Tools available 
on the platform allow users to identify and pool individual 
studies by participant or study characteristics and to select 
the outcome measures to be analyzed. Details and results 
of individual studies, as well as results of meta-analysis of 
pooled data across studies, can be viewed. The data collection 
and analysis are transparent, and the collated data are presented 
in a way that is easily readable, as shown in Figure 1.
In collaboration with the Doctor Evidence service 
  provider, we performed a systematic review of the 
Table 1 studies analyzed
Study Study design Duration of  
follow-up
Study population Prostaglandin analog study arms  
(n = number of patients included  
in analysis)
Alagoz et al4 single-site RCT 180 days Adult patients with newly  
diagnosed glaucoma, visual field  
defects, and iOP $22 mmhg
Bimatoprost 0.03% QD (n = 36) 
Travoprost 0.004% QD (n = 46)
Arcieri et al5 single-site RCT 6 months Adult patients with POAg,  
pseudophakic glaucoma, or aphakic  
glaucoma who needed lower iOP
Bimatoprost 0.03% QD (n = 16) 
Latanoprost 0.005% QD (n = 15) 
Travoprost 0.004% QD (n = 17)
Cantor et al6 Multicenter RCT 6 months Adult patients with POAg or  
OhT and iOP 21–34 mmhg  
after washout
Bimatoprost 0.03% QD (n = 76) 
Travoprost 0.004% QD (n = 81)
Cantor et al7 single-site RCT 6 months Adult patients with POAg or  
OhT and iOP 21–34 mmhg  
after washout
Bimatoprost 0.03% QD (n = 14) 
Travoprost 0.004% QD (n = 12)
Cardascia et al8 single-site RCT 180 days POAg patients ages 40–60 years  
with visual field loss and untreated  
iOP . 20 mmhg
Latanoprost 0.005% QD (n = 9) 
Travoprost 0.004% QD (n = 9)
Dirks et al9 Multicenter RCT 3 months Adult patients with normal-tension  
glaucoma who needed iOP- 
lowering therapy
Bimatoprost 0.03% QD (n = 33) 
Latanoprost 0.005% QD (n = 27)
Gandolfi et al10 Multicenter RCT 3 months Adult patients with glaucoma or  
OhT and iOP 22–34 mmhg  
after washout
Bimatoprost 0.03% QD (n = 109) 
Latanoprost 0.005% QD (n = 105)
ahalpern et al11 Multi-center RCT 48 weeks Black patients with POAg or  
glaucoma and iOP 21–36 mmhg
Latanoprost 0.005% QD (n = 43) 
Travoprost 0.004% QD (n = 49)
Kammer et al12 Multicenter RCT 3 months Adult patients with glaucoma or  
OhT who had inadequate iOP  
control on latanoprost monotherapy
Bimatoprost 0.03% QD (n = 128) 
Travoprost 0.004% QD (n = 132)
Koz et al13 single-site RCT 6 months Previously untreated adult patients with 
POAg or OhT and iOP  
22–36 mmhg
Bimatoprost 0.03% QD (n = 20) 
Latanoprost 0.005% QD (n = 20) 
Travoprost 0.004% QD (n = 20)
netland et al14 Multicenter RCT 1 year Adults with open-angle glaucoma  
or OhT and iOP 24–36 mmhg
Latanoprost 0.005% QD (n = 196) 
Travoprost 0.004% QD (n = 200)
noecker et al15 Multicenter RCT 6 months Adults with glaucoma and/or OhT  
and iOP 22–34 mmhg after washout
Bimatoprost 0.03% QD (n = 133) 
Latanoprost 0.005% QD (n = 136)
noecker et al16 Multicenter RCT 3 months Black adult patients with POAg  
or OhT and iOP 22–34 mmhg  
after washout
Bimatoprost 0.03% QD (n = 49) 
Travoprost 0.004% QD (n = 45)
noecker et al17 Multicenter RCT 3 months Black adult patients with POAg  
or OhT and iOP 22–34 mmhg  
after washout
Bimatoprost 0.03% QD (n = 16) 
Travoprost 0.004% QD (n = 15)
Parrish et al18 Multicenter RCT 12 weeks Adult patients with glaucoma or OhT 
and iOP $ 23 mmhg after washout
Bimatoprost 0.03% QD (n = 136) 
Latanoprost 0.005% QD (n = 136) 
Travoprost 0.004% QD (n = 138)
bVarma et al19 Multicenter RCT 12 weeks Adult patients with glaucoma or OhT 
and iOP $ 23 mmhg after washout
Bimatoprost 0.03% (n = 137) 
Latanoprost 0.005% (n = 136) 
Travoprost 0.004% (n = 138)
Notes: asubgroup analysis of netland 2001study; bsupplementary analysis of study by Parrish et al.18 
Abbreviations: RCT, randomized controlled trial; iOP, intraocular pressure; QD, once daily; POAg, primary open-angle glaucoma; OhT, ocular hypertension.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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peer-reviewed literature to determine the relative efficacy 
of the prostaglandin analogs bimatoprost, latanoprost, 
and travoprost in lowering intraocular pressure (IOP) in 
primary open-angle glaucoma (POAG), normal-tension glau-
coma, and ocular hypertension. We present the results here to 
demonstrate the utility and value of this web-based tool for 
conducting a meta-analysis, leading to efficient development 
of a systematic review.
Methods
Creation of an evidence database  
using the online platform
Relevant studies were identified by the service provider 
through an independent search of the Cochrane Library 
(CDSR, CENTRAL, DARE), Medline, and published sys-
tematic reviews. The search used the terms “glaucoma”, 
“primary”, “open-angle”, “POAG”, “intraocular pressure”, 
“ocular”, “eye”, “pressure”, “hypertension”, “hypertensive”, 
“IOP”, “normotensive”, “normal tension”, “low tension”, 
“bimatoprost”, “Lumigan”, “latanoprost”, “Xalatan”, 
“travoprost”, “Travatan”, “prostaglandin analogs”, and 
“visual field”, and was last updated in September 2009. 
A priori criteria for study inclusion in the database were:
•	 Randomized controlled trial with head-to-head comparison 
of at least two of the following interventions: bimatoprost 
0.03% (Lumigan®, Allergan Inc, Irvine, CA), latanoprost 
0.005% (Xalatan®, Pfizer Inc, New York, NY), and 
travoprost 0.004% (Travatan®, Alcon Laboratories, 
Fort Worth, TX) used as monotherapy in patients with 
glaucoma or ocular hypertension
•	 Mean IOP and/or mean IOP fluctuation reported
•	 Minimum follow-up of 12 weeks
•	 At least 50% of the study population comprised of patients 
diagnosed with POAG, ocular hypertension, or normal-
tension glaucoma, with the rest of the study population 
diagnosed with any type of glaucoma
•	 Study published in English.
Data collection followed a standard procedure used by 
the service provider. Briefly, two evidence-based medical 
specialists read each paper completely and extracted data, 
including the study design, patient characteristics, clini-
cal outcomes, and statistical data. The extracted data were 
imported into a template that was subsequently evaluated 
by proprietary technologies and processes for discrepancies, 
such as mismatches of subgroup and total population data. 
A third evidence-based medical specialist then performed 
an additional quality check of the data and reconciled any 
discrepancies identified prior to final approval of each study 
imported into the comprehensive database.
systematic data review and meta-analysis
Application layers on the database platform permitted review 
of the patient characteristics and outcomes of individual stud-
ies as well as results of meta-analyses of pooled data. The 
primary analyses of mean IOP and mean reduction in IOP 
from baseline were based on data from the earliest time point 
of IOP measurement (typically between 8 am and 10 am) on 
the latest study visit within the timeframe of 12 weeks to six 
months of follow-up. The reduction in diurnal IOP from base-
line was also analyzed based on the latest study visit within 
the timeframe of 12 weeks to six months of follow-up, with 
diurnal IOP defined as the average of IOP measurements taken 
at two or more time points during the day. Other outcomes 
data, including responder rates and achievement of target pres-
sure levels, were also included in the database in the event that 
researchers decided to analyze additional endpoints.
Meta-analyses used the inverse variance method of 
weighting data for pooling.1 Heterogeneity of results across 
studies was tested with the Cochrane Q Chi-square test.2 
Table 2 Reasons for exclusion of studies from the analyses shown
Study Reason
Cantor et al7 •   Missing error measurement needed for inclusion 
in meta-analysis of mean iOP
•   Missing change in diurnal iOP data needed for 
inclusion in analysis of change in diurnal iOP 
from baseline
halpern et al11 •   Missing mean iOP data from a study visit after 
12–26 weeks of treatment that would be needed 
for inclusion in meta-analysis of mean iOP
•   Missing change in diurnal iOP data needed for 
inclusion in analysis of change in diurnal iOP 
from baseline
netland et al14 •   Missing error measurement needed for inclusion 
in meta-analysis of mean iOP
•   Missing change in diurnal iOP data needed for 
inclusion in analysis of change in diurnal iOP 
from baseline
noecker et al17 •   Missing error measurement needed for inclusion 
in meta-analysis of mean iOP
•   Missing diurnal iOP measurements needed for 
inclusion in analysis of change in diurnal iOP 
from baseline
noecker et al16 •   Missing error measurement needed for inclusion 
in meta-analysis of mean iOP
•   Missing diurnal iOP measurements needed for 
inclusion in analysis of change in diurnal iOP 
from baseline
Varma et al19 •   This paper reports the same patients/data as 
Parrish 2003, so it could not be included as an 
independent data source for the same analysesTherapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Random-effects models were used for analyses because of 
the heterogeneity of treatment effects across studies.3
Results
The literature search identified 260 studies that were 
potentially relevant for inclusion in the database. Of these 
studies, 242 were rejected because they did not meet 
the inclusion criteria (reasons included not being a clinical 
study [n = 23], not being a head-to-head randomized controlled 
trial [n = 32], a crossover rather than parallel-group study 
design [n = 7], less than half of the population diagnosed with   
POAG, ocular hypertension, or normal-tension glaucoma 
[n = 53], did not compare at least two of the   following: 
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% 
as monotherapy [n = 110], mean IOP or mean IOP fluctuation 
not reported [n = 7], inadequate follow-up period [n = 8], not in 
English [n = 1], and meeting abstract with insufficient informa-
tion available [n = 1]). The remaining 18 studies were random-
ized controlled studies comparing the prostaglandin analogs. 
These studies satisfied the inclusion criteria and were assigned 
for data extraction. Two of these 18 studies were rejected from 
the evidence database, one because there were discrepancies 
in the manuscript and no author clarification was received, and 
the other because outcomes were stratified by race rather than 
by treatment. The remaining 16 studies4–19 were included in the 
evidence database and analyzed.
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Koz 2007
Arcieri 2005
Parrish 2003
Overall
Noecker 2003
Alagoz 2008
Koz 2007
Arcieri 2005
Kammer 2010
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Overall
Cantor 2006
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Figure 1 Forest plots of the differences in intraocular pressure between prostaglandin analogs in individual studies and in the meta-analyses of the pooled data.
Abbreviation: iOP, intraocular pressure.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
287
Online tool for systematic reviews and meta-analysis
Details of these 16 studies, including the study design, 
study duration, study population, and drugs tested, are listed 
in Table 1. Data were available from more of these studies 
for the primary outcomes chosen for analysis, ie, mean IOP 
and mean change in diurnal IOP from baseline, than for other 
efficacy outcomes that might be of interest, such as responder 
rates or achievement of target pressure levels, which could 
also be analyzed using the database. Of the 16 studies, several 
were not included in either of the meta-analyses presented 
because they did not report data for the primary outcomes, or 
data were reported without standard deviations or other error 
measurements. The specific reasons for studies not being 
included in the analyses shown are listed in Table 2.
Differences in mean IOP between the prostaglandin 
analogs were evaluated by meta-analysis (Figure 1). The 
effects of bimatoprost and latanoprost on mean IOP in the 
  morning after 12–26 weeks of treatment were compared in 
826 patients in five studies.5,10,13,15,18 The results demonstrated 
substantial heterogeneity across studies (Q = 15.6, P = 0.004). 
Meta-analysis of the data showed that mean IOP was 1 mmHg 
lower with bimatoprost than with latanoprost (mean dif-
ference −0.96 mmHg, 95% confidence interval [CI] −1.8, 
−0.12, P = 0.025). Six studies that reported mean data with 
estimates of variance compared the effects of bimatoprost and 
travoprost on mean IOP in the morning after 12–26 weeks 
of treatment.4–6,12,13,18 Data were available from a total of 
846 patients treated with bimatoprost or travoprost in these 
studies. Meta-analysis of the data showed that mean IOP was 
0.8 mmHg lower with bimatoprost than with travoprost (mean 
difference −0.82 mmHg, 95% CI −1.58, −0.07, P = 0.033). 
The effects of latanoprost and travoprost on mean IOP in 
the morning after 12–26 weeks of treatment were compared 
in 364 patients in four studies.5,8,13,18 Meta-analysis of the 
data showed no statistically significant difference in mean 
IOP between latanoprost and travoprost (mean   difference 
−0.06 mmHg, 95% CI −0.62, 0.50, P = 0.841).
The effects of bimatoprost and latanoprost on the change 
in diurnal IOP from baseline after 12–26 weeks of treatment 
were compared in two studies,9,18 but pooling of the data was 
not possible because no estimate of variance was reported in 
one of the studies.9 In the study reported by Parrish et al,18 
the mean reduction in diurnal IOP from baseline at week 12 
was 0.3 mmHg larger with bimatoprost than with latanoprost 
(n = 273, Figure 2), while in the study reported by Dirks et al,9 
the mean reduction in diurnal IOP from baseline at week 13 
was 1.1 mmHg larger with bimatoprost than with latanoprost 
(n = 60, P = 0.035, Figure 2). Differences in results between 
the studies may reflect differences in the patient populations 
and their treatment history. Patients in the study reported by 
Dirks et al9 were diagnosed with normal-tension glaucoma, 
while patients in the study reported by Parrish et al18 were 
diagnosed with ocular hypertension or glaucoma associated 
with elevated IOP. Half of the patients enrolled in the study 
reported by Parrish et al18 were being treated with latanoprost 
when they were screened for study entry. The treatment 
history of patients enrolled in the study by Dirks et al9 was 
not reported.
The effects of bimatoprost and travoprost on the change 
in diurnal IOP from baseline after 12–26 weeks of treat-
ment were compared in 534 patients in two studies.12,18 
Meta-analysis of the data showed that the mean reduction in 
diurnal IOP from baseline was 0.7 mmHg larger in patients 
treated with bimatoprost than in patients treated with travo-
prost (mean difference −0.66 mmHg, 95% CI −1.13, −0.19, 
P = 0.006, Figure 3).
Only the study reported by Parrish et al18 compared the 
effects of latanoprost and travoprost on the change in diurnal 
IOP from baseline after 12–26 weeks of treatment. In that 
study, the mean reduction in diurnal IOP from baseline at 
week 12 was 0.3 mmHg larger with latanoprost than with 
travoprost (n = 274, Figure 4).
Discussion
Clinical and formulary decision-making should be based 
on the highest quality of evidence available with respect to 
the effectiveness of treatment and product differentiation. 
Systematic reviews of drug efficacy are useful for quali-
tative evaluation of study results and differences in drug 
efficacy. Quantitative evaluation of differences in drug 
efficacy requires meta-analysis of the pooled data with 
associated statistics. There is strong evidence that lower IOP 
improves outcomes for patients with glaucoma and ocular 
hypertension.20–22 Conduct of a systematic review and meta-
analysis using a web-based platform provided evidence that 
use of bimatoprost achieved approximately a 1 mmHg lower 
mean IOP compared with latanoprost or travoprost and that 
this difference was statistically significant. There was no 
statistically significant difference between latanoprost and 
travoprost in mean IOP. These findings are consistent with 
previously published meta-analyses of the efficacy of the 
prostaglandin analogs.23,24 Changes in diurnal IOP from 
baseline were reported in fewer studies, and meta-analysis 
was possible only for the comparison of bimatoprost and 
  travoprost. Nonetheless, the results were consistent with 
greater IOP-lowering of bimatoprost compared with latano-
prost or travoprost.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Figure 2 Mean change in diurnal intraocular pressure from baseline in individual studies comparing bimatoprost with latanoprost.
Abbreviation: iOP, intraocular pressure.
The meta-analysis previously reported by Aptel et al24 
evaluated change from baseline IOP rather than mean IOP, 
and at least 90% of the patients in each included study had 
to be diagnosed with POAG or ocular hypertension. The 
analysis was similar to ours in that it included only studies 
comparing at least two prostaglandin analogs, with a total 
of eight studies involving 1608 patients included. Two of 
the studies in the meta-analysis by Aptel et al were excluded 
from our meta-analysis of mean IOP because their duration 
was only one month, and we required a study duration of at 
least 12 weeks because latanoprost may not reach full effect 
after one month of treatment.25 Another two studies included 
in their meta-analysis14,17 were included in our database, but 
not our meta-analysis, because no error measurements were 
reported (Aptel et al calculated estimates of standard devia-
tions for their analysis). In addition to four shared studies, 
our   meta-analysis of mean IOP included five additional 
recent studies for a total of nine studies, with data analyzed 
for 1518 patients. Despite these differences, comparable 
conclusions were drawn. Aptel et al reported larger reduc-
tions in IOP from baseline at 8 am in bimatoprost-treated 
eyes than with latanoprost or travoprost, and we similarly 
reported lower IOP with bimatoprost than with latanoprost 
or travoprost at the earliest time point in the day. In addition, 
both Aptel et al and our group found no significant difference 
in efficacy between latanoprost and travoprost.
In our systematic review of IOP-lowering with the pros-
taglandin analogs, the service provider entered all available 
data from the included studies into individual data templates. 
For each outcome measure evaluated, the results of each 
individual study could be visualized, and a summary state-
ment of the results was provided. When meta-analysis was 
Parrish 2003
Kammer 2010
Overall
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Figure 3 Forest plot of the difference in the change in diurnal intraocular pressure from baseline between bimatoprost and travoprost in individual studies and in the meta-
analysis of the pooled data.
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possible, the meta-analysis results could also be visualized, 
and a summary statement was provided.
A fixed-effect model of meta-analysis is based on a math-
ematical assumption that every study is evaluating a common 
treatment effect. The summary treatment effect estimate 
resulting from this method of meta-analysis is the “true” or 
“fixed” treatment effect, and the CI describes the uncertainty 
of the estimate. Often, this underlying assumption may not be 
correct, because variation in study results is greater than would 
be expected by chance, indicating important underlying differ-
ences in study populations or methods. When this is the case, an 
alternative approach to meta-analysis is to use a random-effects 
model. The random-effects model assumes that the treatment 
effects in the individual studies may be different from each other, 
and the most common random-effects model also assumes that 
these different effects are normally distributed. Therefore, the 
meta-analysis estimates the mean and standard deviation of 
the different treatment effects. In our study, Chi-square tests 
indicated heterogeneity of treatment effects across studies, so 
random-effects models were used for meta-analysis.
Doctor Evidence, the online provider used in this report, 
uses traditional (and standard) meta-analysis methods and 
statistics, but the web-based platform offers three key advan-
tages over traditional systematic reviews and meta-analysis. 
First, the process of performing meta-analysis is standardized, 
and the software provides an appropriate type of analysis for 
the data. For example, the meta-analysis of IOP-lowering with 
the prostaglandin analogs used random-effects rather than 
fixed-effects meta-analysis models because of the heterogene-
ity of treatment effects across studies.   Second, details of the 
studies and analysis used are transparent. The calculations 
used in the statistical models are provided. Third, the results 
can be rapidly updated with new evidence. The database can 
be updated and meta-analysis results made available within 
48 hours of publication of a new study.
The service is not without cost and may exceed the 
budget of an individual medical researcher, but could be 
within a departmental budget. Users such as managed care 
formulary managers who need to repeat meta-analyses 
when new clinical data become available may realize cost 
savings over the long term because of the ability to update 
the database and meta-analysis rapidly. There is also a 
learning curve in becoming adept at navigating the database 
and accessing all the information and analyses contained 
on the platform. Nonetheless, formulary managers and oth-
ers may find the online service to be a useful tool, because 
it facilitates the process of and shortens the timeline for 
performing systematic reviews and meta-analyses. The 
software provided can be used for meta-analysis of any 
endpoint and allows rapid modification of the analysis to 
facilitate critical appraisal of the evidence. For example, 
it is possible to select and deselect studies for inclusion in 
the analysis, which may be useful if, for example, there is a 
desire to limit the analysis to studies with study populations 
most similar to the patient population of interest.
In summary, transparent evidence-based decisions 
require the use of systematic reviews for evidence synthesis. 
We have demonstrated that collaboration with an online pro-
vider of systematic review services and software facilitates 
the process of developing up-to-date systematic reviews and 
meta-analysis of clinical evidence. Both the collection and 
the analysis of the data are transparent, and the analysis can 
be rapidly updated to include new evidence. The systematic 
review of prostaglandin analog efficacy in glaucoma and 
ocular hypertension performed in collaboration with the 
web-based service provider showed that bimatoprost has 
greater IOP-lowering efficacy than latanoprost or travoprost, 
consistent with results of previous meta-analyses of clinical 
trial data. These results demonstrate that the online service 
may be a valuable tool for generating systematic reviews and 
meta-analysis useful in formulary decision-making.
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Figure 4 Mean change in diurnal intraocular pressure (iOP) from baseline in a single 
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